19 completed, 1 enrolling by invitation, 1 recruiting, 1 suspended. 14 Phase 4, 4 Phase 1, 2 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 14 | Completed 10, Enrolling by invitation 1, Recruiting 1, Suspended 1, Terminated 1 |
| Phase 1 | 4 | Completed 4 |
| Not applicable | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Quinapril: new trials by email Literature Review of Quinapril trials Research Report on Quinapril
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Coronavirus (COVID-19) ACEi/ARB Investigation Thiazide or Thiazide-like diuretics, Calcium Channel Blockers, ACE inhibitor - Hypertension, COVID-19 | Phase 4 | Suspended | National University of Ireland, Galway, Ireland | 2414 | 2020-04-30 | 2020-06-30 |
| ACEI or ARB and COVID-19 Severity and Mortality in US Veterans ACEI/ARB, Non-ACEI/ARB, ACEI - Hypertension, COVID | Completed | University of Utah | 22213 | 2020-01-19 | 2021-04-28 | |
| Diabetic Autonomic Neuropathy and Left Ventricular Function Quinapril, Losartan, Quinapril + Losartan - Diabetes Mellitus | Phase 4 | Completed | AHEPA University Hospital | 59 | 2017-01-01 | 2023-02-06 |
| NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients RAS-antagonist and beta-blocker up-to maximal dosages, RAS-antagonist and beta-blocker none or at stable dose - Heart Diseases, Diabetes Mellitus, Type 2 | Phase 4 | Recruiting | Martin Huelsmann | 2400 | 2016-02-01 | 2023-03-14 |
| Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery ACEI continuation, ACEI omission - Hypotension on Induction | Phase 4 | Completed | University of Nebraska | 291 | 2015-06-01 | 2023-09-25 |
| Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF Aggressive Blood Pressure control - Atrial Fibrillation | Phase 4 | Completed | Nova Scotia Health Authority | 184 | 2009-12-01 | 2017-06-20 |
| A Non Interventional Study To Asses The Safety, Effectiveness And Tolerability Of Quinapril (Acupil®) In An Indian Population quinapril - Hypertension | Completed | Pfizer | 329 | 2009-06-01 | 2011-05-04 | |
| Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial Statin, ACE inhibitor, Placebo - Type 1 Diabetes | Phase 3 | Completed | University of Cambridge | 443 | 2009-01-01 | 2018-06-28 |
| Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment Any antihypertensive medication alone or in combination, Ambulatory blood pressure monitoring - Essential Hypertension, Cardiovascular Disease | Phase 4 | Completed | University of Vigo | 21983 | 2008-09-01 | 2018-08-28 |
| Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension Quinapril (Accupril) plus Alpha Lipoic Acid, accupril, placebo, accupril, alpha lipoic acid - Diabetes, Hypertension | Not applicable | Completed | InVasc Therapeutics, Inc. | 23 | 2008-07-01 | 2011-05-05 |
| High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine in the Treatment of High-Risk Hypertensive Patients Quinapril 40 mg, Quinapril 10 mg and amlodipine 5 mg - Hypertension | Phase 4 | Terminated | Montreal Heart Institute | 40 | 2006-04-01 | 2008-05-06 |
| High Dose Candesartan Versus Quinapril for Restenosis Prophylaxis After Stent Angioplasty candesartan (drug) or quinapril (drug) - Arterial Occlusive Diseases | Not applicable | Completed | Technische Universität Dresden | 22 | 2004-05-01 | 2006-09-12 |
| Non-Comparative Study To Evaluate Changes In FMD After Quinapril Therapy In Hypertensive Women quinapril, Laser Doppler imaging - Menopause, Hypertension | Phase 4 | Completed | Pfizer | 70 | 2003-10-01 | 2007-04-30 |
| Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg, Accuretic™ Tablets 20 mg/25 mg - Healthy | Phase 1 | Completed | Mylan Pharmaceuticals Inc | 60 | 2003-08-01 | 2024-04-24 |
| Food Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg, Accuretic™ Tablets 20 mg/25 mg - Healthy | Phase 1 | Completed | Mylan Pharmaceuticals Inc | 44 | 2003-08-01 | 2024-04-24 |
| A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension quinapril 20 mg, quinapril 20 mg plus hydrochlorothiazide 12.5 mg, quinapril 40 mg - Hypertension | Phase 4 | Completed | Pfizer | 200 | 2002-12-01 | 2008-04-10 |
| Food Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg Quinapril Hydrochloride Tablets 40 mg, Accupril® Tablets 40 mg - Healthy | Phase 1 | Completed | Mylan Pharmaceuticals Inc | 24 | 2002-12-01 | 2024-04-24 |
| Fasting Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg Quinapril Hydrochloride Tablets 40 mg, Accupril® Tablets 40 mg - Healthy | Phase 1 | Completed | Mylan Pharmaceuticals Inc | 60 | 2002-12-01 | 2024-04-24 |
| QWISE - Study of Quinapril in Women With Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial Ischemia Quinapril, Placebo - Ischemic Heart Disease | Phase 4 | Completed | University of Florida | 78 | 2000-05-01 | 2012-04-13 |
Showing 20 of 23. Sign in to see all of them.
Hypertension (8) · Diabetes Mellitus, Type 2 (3) · Cardiovascular Diseases (2) · Diabetes Mellitus (2) · Renal Insufficiency, Chronic (2) · Albuminuria (1) · Arterial Occlusive Diseases (1) · Atrial Fibrillation (1) · COVID-19 (1) · Coronavirus Infections (1) · Diabetes Mellitus, Type 1 (1) · Diabetic Neuropathies (1) · Essential Hypertension (1) · Heart Diseases (1) · Hyperkalemia (1)
Mylan Pharmaceuticals Inc (4) · Pfizer (3) · Montreal Heart Institute (2) · University of Vigo (2) · AHEPA University Hospital (1) · Aristotle University Of Thessaloniki (1) · Baylor Research Institute (1) · InVasc Therapeutics, Inc. (1) · Martin Huelsmann (1) · National University of Ireland, Galway, Ireland (1) · Nova Scotia Health Authority (1) · Technische Universität Dresden (1) · University of Cambridge (1) · University of Florida (1) · University of Nebraska (1)
United States (9) · Canada (3) · Spain (3) · Australia (1) · Austria (1) · Germany (1) · Greece (1) · Hungary (1) · India (1) · Ireland (1) · Netherlands (1) · New Zealand (1) · Turkey (Türkiye) (1) · United Kingdom (1)
James D Carlson, Pharm. D. (4) · Ramon C Hermida, PhD (2) · Adam P Bress, PharmD, MS (1) · Carl J Pepine, MD (1) · David B Dunger, Professor (1) · Jacques de Champlain, MD, PhD (1) · Jason F Shiffermiller, MD, MPH (1) · Jean-Lucien Rouleau, M.D (1) · John William McEvoy, MBBCh MHS (1) · Martin Huelsmann, Doz.Dr. (1) · Michel White, MD (1) · Ratika Parkash, MD MSc (1) · Simon de Denus, B. Pharm, MSc (1) · Syed T. Rahman, MD (1)
PMID 19407805, PMID 21617110, PMID 21884956, PMID 21982660, PMID 22416821, PMID 25392936, PMID 26399404, PMID 27221952, PMID 28228428, PMID 29091568, PMID 30261084, PMID 31641769, PMID 32108022, PMID 33100044, PMID 33891615, PMID 34530738, PMID 38124088, PMID 42056188, PMID 42718842
U01HL064924 (1)